Article
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2011
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T
Abstract excerpt
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment option in this setting. However, its use in clinical practice has several relevant implications and open issues. In order to choose the best treatment, a molecular characterization is now mandatory, as part of baseline diagnostic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.